摘要
目的探讨外周血LunX mRNA联合CEA、SCCA、CYFRA21-1三项肿瘤标志物检测在非小细胞肺癌(NSCLC)患者临床诊断中的价值。方法应用实时荧光定量RT-PCR技术和化学发光免疫分析法,分别对NSCLC、乳腺癌、胃癌、肺炎患者及健康体检人群外周血中LunX mRNA和三项肿瘤标志物水平进行检测。结果NSCLC患者外周血中检测到LunX mRNA,阳性表达率为78.6%(44/56),在乳腺癌、胃癌、肺炎患者健康体检人群外周血中LunX mRNA检测为阴性,但是其他三项肿瘤标志物在NSCLC、乳腺癌、胃癌外周血中检测为阳性,在肺炎患者和健康体检者中检测为阴性。外周血中LunX mRNA表达水平及其阳性表达率与NSCLC患者TNM病理分期密切相关(P<0.05)。结论NSCLC患者外周血中LunX mRNA表达特异性高,LunX mR-NA联合三项肿瘤标志物检测对NSCLC临床诊断提供重要参考依据。
Objective To study the diagnostic value of LunX mRNA combined three tumor markers in patients with non-small cell lung cancer （NSCLC）. Methods LunX mRNA was determined by quantitative real- time PCR. Three tumor markers （CEA, SCCA and CYFRA21-1） in peripheral blood of NSCLC patients and other controls were detected by chemiluminescence immunoassay. Results The positive rate of LunX mRNA was 78.6% （44/56） in patients with NSCLC, but All of controls was negative. CEA, SCCA and CYFRA21-1 were positive in patients with either NSCLC or gastric cancer and breast cancer, but were negative in pneumonia and healthy volunteers. The positive expression level of LunX mRNA was correlated with the pathologic stage of NSCLC（P〈0.01）. Conclusion LunX mRNA is of specific expression in peripheral blood of patients with NSCLC, LunX mRNA detection combined three tumor markers will provide significant laboratory evidence for clinical diagnosis of NSCLC.
出处
《实验与检验医学》
CAS
2009年第6期591-594,共4页
Experimental and Laboratory Medicine
